Skip to main content
SpringerLink
Log in

Markers and Immunoprofile of Renal and Urinary Tract Tumors

  • Chapter
  • First Online:
Immunohistochemistry in Tumor Diagnostics

  • 184 Accesses

Abstract

Diagnostic antibody panel for renal tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McGregor K, David KK, et al. Diagnosing primary and metastatic renal cell carcinoma. Am J Surg Pathol. 2001;25:1485–92.

    Article  CAS  PubMed  Google Scholar 

  2. Zhao W, Tian B, Wu C, et al. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma. Pathol Res Pract. 2015;211(4):303–7.

    Article  CAS  PubMed  Google Scholar 

  3. Ordóñez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012;19(3):140–51.

    Article  PubMed  Google Scholar 

  4. Sangoi AR, Ohgami RS, Pai RK, et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24:412–24.

    Article  CAS  PubMed  Google Scholar 

  5. Tong G-X, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218–12227.

    Article  CAS  PubMed  Google Scholar 

  6. Wang H-Y, Mills SE. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am J Surg Pathol. 2005;29:640–6.

    Article  PubMed  Google Scholar 

  7. Avery AK, Beckstead J, Renshaw A, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203–10.

    Article  CAS  PubMed  Google Scholar 

  8. Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract. A useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol. 2003;2:178–86.

    Article  Google Scholar 

  9. Kuroda N, Guo L, Toi M, et al. Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma. Appl Immunohistochem Mol Morphol. 2001;9(4):315–8.

    Article  CAS  PubMed  Google Scholar 

  10. Li G, Bilal I, Gentil-Perret A, et al. CA9 as a molecular marker for differential diagnosis of cystic renal tumors. Urol Oncol. 2012;30(4):463–8.

    Article  PubMed  Google Scholar 

  11. Donato DPI, Johnson MT, Yang XJ, et al. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology. 2011;59(6):1229–39.

    Article  PubMed  Google Scholar 

  12. Sangoi AR, Karamchandani J, Kim J, et al. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma, a review of PAX-8, PAX-2, hKIN-1. RCCma, CD10. Adv Anat Pathol. 2010;17(6):377–93.

    Article  CAS  PubMed  Google Scholar 

  13. Lin F, Zhang PL, Yang XJ, et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol. 2007;31(3):371–81.

    Article  PubMed  Google Scholar 

  14. Alexiev BA. Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 (TFE3) fusion. J Cytol Histol. 2013;4(2):173.

    Article  Google Scholar 

  15. Chamberlain BK, McClain CM, Gonzalez RS, et al. Alveolar soft part sarcoma and granular cell tumor: an immunohistochemical comparison study. Hum Pathol. 2014;45:1039–44.

    Article  CAS  PubMed  Google Scholar 

  16. Argani P, Aulman S, Illei PB, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34:1395–406.

    Article  PubMed  Google Scholar 

  17. Oudijk L, Gaal J, de Krijger RR. The role of immunohistochemistry and molecular analysis of succinate dehydrogenase in the diagnosis of endocrine and non-endocrine tumors and related syndromes. Endocr Pathol. 2019;30:64–73.

    Article  CAS  PubMed  Google Scholar 

  18. Gupta S, Swanson A, Chen Y-B, et al. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Hum Pathol. 2019;91:114–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology. 2012;44(4):285–92.

    Article  CAS  PubMed  Google Scholar 

  20. Harrison WJ, Andrici J, Maclean F, et al. Fumarate hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings. Am J Surg Pathol. 2016;40(5):599–607.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Trpkov K, Hes O, Agaimy A, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol. 2016;40:865–75.

    Article  PubMed  Google Scholar 

  22. Lau HD, Chan E, Fan AC, et al. A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol. 2020;44:98–110.

    Article  PubMed  Google Scholar 

  23. Skalaa SL, Wangab X, Zhanga Y, et al. Next-generation RNA sequencing-based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur Urol. 2020;78(1):63–74.

    Article  Google Scholar 

  24. Tong K, Hu Z. FOXI1 expression in chromophobe renal cell carcinoma and renal oncocytoma: a study of the cancer genome atlas transcriptome-based outlier mining and immunohistochemistry. Virchows Arch. 2021;478:647–58.

    Article  CAS  PubMed  Google Scholar 

  25. Wu X-R, Lin J-H, Walz T, et al. Mammalian uroplakins: a group of highly conserved urothelial differentiation-related membrane proteins. J Biol Biochem. 1994;269:13716–24.

    CAS  Google Scholar 

  26. Lobban ED, Smith BA, Hall GD, et al. Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol. 1998;153:1957–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Yuasa T, Yoshiki T, Isono T, et al. Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol. 1999;6:286–92.

    Article  CAS  PubMed  Google Scholar 

  28. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683–7.

    Article  CAS  PubMed  Google Scholar 

  29. Higgs JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31(5):673–80.

    Article  Google Scholar 

  30. Esheba GE, Longacre TA, Atkins KA, et al. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferation. Am J Surg Pathol. 2009;33(3):347–53.

    Article  PubMed  Google Scholar 

  31. Ellis CL, Chang AG, Cimino-Mathews A, et al. GATA-3 expression in the differential diagnosis of adenocarcinoma of the urinary bladder. Am J Surg Pathol. 2013;37:1756–60.

    Article  PubMed  Google Scholar 

  32. Rao Q, Williamson SR, Lopez-Beltran A, et al. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. Mod Pathol. 2013;26:725–32.

    Article  CAS  PubMed  Google Scholar 

  33. Lopez-beltran A, Motironi R, Vidal A, et al. Urothelial dysplasia of the bladder. Anal Quant Cytopathol Histopathol. 2013;35:121–9.

    Google Scholar 

  34. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium. An analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Carl-Thiem-Klinikum, Institut für Pathologie, Cottbus, Germany

    Muin S. A. Tuffaha

  2. Vivantes Klinikum Neukölln, Institut für Pathologie, Berlin, Germany

    Hans Guski

  3. Universität Bonn, UKB, Institut für Pathologie, Bonn, Germany

    Glen Kristiansen

Authors
  1. Muin S. A. Tuffaha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Guski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glen Kristiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tuffaha, M.S.A., Guski, H., Kristiansen, G. (2023). Markers and Immunoprofile of Renal and Urinary Tract Tumors. In: Immunohistochemistry in Tumor Diagnostics. Springer, Cham. https://doi.org/10.1007/978-3-031-45024-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-45024-2_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-45023-5

  • Online ISBN: 978-3-031-45024-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation